Badrul Chowdhury jumps ship at the FDA and moves to AstraZeneca, joining an exodus of agency officials
Twenty-year FDA veteran Badrul Chowdhury, most recently director of the Center for Drug Evaluation and Research’s (CDER) Division of Pulmonary, Allergy and Rheumatology Products, has taken a job this month as senior vice president at AstraZeneca.
AstraZeneca tells Endpoints News that Chowdhury will be moving into a top research job, taking on the role of senior vice president of research development at AstraZeneca and MedImmune, where he will be heading up the Respiratory, Inflammation, and Autoimmunity, Innovative Medicine and Early Development Biomed Unit.
Chowdury joined the agency in 1997 and left on 16 April. And Chowdury isn’t the only one to leave in recent months for an industry job, FDA said.
Sarah Pope Miksinski, former director of the Office of New Drug Products in FDA’s Office of Pharmaceutical Quality, left the agency in February, also for AstraZeneca. And last July, Geoffrey Kim, former director of FDA’s Division of Oncology Products moved to AstraZeneca to become its VP of oncology and head of oncology strategic combinations.
Meanwhile, Jean-Marc Guettier, former director of FDA’s Division of Metabolism and Endocrinology Products, left FDA in December 2017 for Sanofi, Niraj Mehta, former associate director for global regulatory policy at FDA moved over to Merck as a director in March 2018, and Thomas Cosgrove, former director of FDA’s Office of Manufacturing Quality in the Office of Compliance, left in November 2017 to join the law firm Covington & Burling.
Regulatory consulting firms like Greenleaf Health also frequently poach former FDAers with decades of experience, including former Office of New Drugs Director John Jenkins.
Questions have been raised in recent years on the revolving door between industry and FDA, particularly as experience at the agency can lead to lucrative salaries and create conflicts where relationships between industry and FDA are already cozy.
Back in 2015, the European Medicines Agency tightened its policy on the revolving door, noting that if necessary, it would begin verifying if previous scientific reviews in which a person jumping ship to industry had been compromised.
On the flip side, FDA relies on industry funds to do its work, often hires industry experts and uses outside expertise from pharmaceutical companies to inform guidance documents and rulemakings.
FDA Commissioner Scott Gottlieb and his predecessor, Robert Califf, were both criticized ahead of their confirmation hearings for being too closely linked to industry, but both commissioners have also shown how their experience can be utilized in the top job.
First published here. Regulatory Focus is the flagship online publication of the Regulatory Affairs Professionals Society (RAPS), the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Email firstname.lastname@example.org for more information.
Image: Badrul Chowdbury. FDA